中國Walvax的mRNA COVID疫苗在海外獲得首個批准

Recently Yahoo New on-line reported the following:

China Walvax's mRNA COVID vaccine obtains first approval overseas

Thu, September 29, 2022 at 11:02 PM

JAKARTA/BEIJING (Reuters) -The Indonesian food and drugs agency (BPOM) said on Thursday it has approved the emergency use of an mRNA COVID-19 vaccine developed by China's Walvax Biotechnology.

It is the first authorization for a China-developed COVID shot based on the novel mRNA technology, which Pfizer/BioNTech and Moderna also use in their COVID vaccines, after more than two years of development.

The AWcorna shot, which is designed based on the original strain of the coronavirus, has yet to generate efficacy readings from large trials to show how well it can reduce the risk of COVID cases and deaths from the disease.

China has not yet authorized local use of the shot, previously known as ARCoV.

Walvax co-developed the vaccine with Suzhou Abogen Biosciences and a Chinese military-backed institution.

The two firms are also separately working on their own coronavirus variant-targeting candidates based on the mRNA technology.

(Reporting by Stanley Widianto in Jakarta and Roxanne Liu in Beijing; Editing by Kirsten Donovan)

Translation

雅加達/北京（路透社）- 印度尼西亞食品和藥物管理局（BPOM）週四表示，它已批准緊急使用由中國 Walvax 生物技術公司開發的 mRNA COVID-19 疫苗。

這是中國開發的基於新型 mRNA 技術的 COVID 疫苗的首次授權，輝瑞 / BioNTech 和 Moderna 曾經過兩年多的開發後也將其用於其 COVID 疫苗。

AWcorna 疫苗是根據冠狀病毒的原始毒株設計的, 尚未從大型試驗中產生療效讀數，以顯示它在降低 COVID 病例和死亡的風險。

中國尚未授權在本地使用這種疫苗，以前稱為 ARCoV。

Walvax 與蘇州阿原生物和一家中國軍方支持的機構共同開發了這種疫苗。

這兩家公司還分別基於 mRNA 技術開發自己的冠狀病毒變異靶向候選藥物。

       So, Indonesia has approved the emergency use of an mRNA COVID-19 vaccine developed by China while China has yet to use it themselves.